By Dr Blythe Sather2023-07-07T10:47:32
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T06:15:00Z
Contributor Professor Donald E Ingber, By Drug Target Review
2023-03-30T12:35:58
Sponsored by Sartorius
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2026-05-26T09:05:00
Contributor Thomas Clozel M.D., By Drug Target Review
2023-03-08T16:29:20
Sponsored by Bio-Techne
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2026-05-19T09:46:00
Contributor Dr Nitza Thomasson
Site powered by Webvision Cloud